Dara Erck Joins Aeras As V.P., External Affairs

ROCKVILLE, Md., June 15, 2015 /PRNewswire-USNewswire/ -- Aeras is pleased to announce that Dara Erck joins the organization today as the Vice President of External Affairs. As a member of the senior leadership team, Ms. Erck will be responsible for resource mobilization, advocacy, and communications.

"Dara's extensive experience in global health, resource mobilization, and finance and planning is a valuable resource that will help Aeras meet its goal of developing new effective and affordable tuberculosis vaccines," said Tom G. Evans, M.D., Aeras CEO.

Ms. Erck has more than 15 years' experience in the global health field. She previously was the managing director of Erck Consulting, where she provided long-term consulting services for the Bill & Melinda Gates Foundation, The Flowers Foundation, and other clients in the global health arena. Before launching Erck Consulting, Ms. Erck served as Director of Finance and Planning at the International Aids Vaccine Initiative (IAVI); Consultant for Global Health Solutions at Computer Sciences Corporation; Program Manager, Clinical Research at the Genzyme Corporation; and Assistant Operations Manager, AIDSMark at Population Services International (PSI).

Ms. Erck has a Master of International Affairs degree from Columbia University and a Bachelor's degree in International Affairs from The George Washington University.

About Aeras

Aeras is a nonprofit, global biotech advancing the development of new tuberculosis vaccines for the world, in partnership with other biotech, pharmaceutical, and academic organizations. Aeras has 150 employees from over 20 countries around the world, and has offices in the U.S., Africa, and Asia. Aeras is funded primarily by the Bill and Melinda Gates Foundation and European donor governments. Support also is received from the U.S. government as well as partnerships and collaborations with universities and pharmaceutical companies. www.aeras.org

CONTACT: Ellen Wilcox, [email protected]
 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.